AzTrials
AzTrials

Schizophrenia and Disorders With Psychotic FeaturesPhase 4NCT00748566

One-Year Trial Of Oral Ziprasidone In Patients With Metabolic Syndrome

A Phase 4 study testing Ziprasidone HCL (oral) in people with Schizophrenia and Disorders With Psychotic Features, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 32 sites in Canada.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Ziprasidone HCL (oral)
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
172 participants
Where
32 sitesCanada
Study dates
Dec 2008to May 2012
Phase
Phase 4
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Subject must present at least 2 of the following risk factors of MS at screening: Elevated waist circumference: >102 cm in men and >88 cm in women; Elevated triglycerides (TGs): ≥1.7 mmol/L (≥150 mg/dL); Reduced HDL-Cholesterol: <1.03 mmol/L (<40 mg/dL) in men and <1.3 mmol/L (<50 mg/dL) in women; Elevated fasting glucose: ≥ 5.6 mmol/L.
  • According to the clinical judgment of the investigator, the risk factors for MS have developed in close temporal relationship to starting an antipsychotic medication.
  • Substitution to a less metabolically disruptive antipsychotic medication is considered.

Who cannot join

  • Subjects with contraindication(s) to the use of Ziprasidone according to Canadian prescribing information.
  • Subjects with a history of treatment resistance.
  • Subjects with any medical condition (e.g. pre-existing diabetes, pre-existing dyslipidemia, thyroid pathology) or taking any concomitant medication (e.g. topiramate or other weight loss-promoting agents, hypoglycemic agents, hypolipemic agents), that may confound the evaluation of the study drug.
  • Body mass index ≥ 40 at baseline.

Trial locations and contacts

32 sites in 1 country.

32 sites in 1 country

Canada32 sites
  • Pfizer Investigational Site

    Bathurst, New Brunswick, E2A 2Z6

  • Pfizer Investigational Site

    Burlington, Ontario, L7R 4E2

  • Pfizer Investigational Site

    Calgary, Alberta, T2N 2T9

  • Pfizer Investigational Site

    Calgary, Alberta, T2N 4Z6

  • Pfizer Investigational Site

    Chatham, Ontario, N7L 1B7

  • Pfizer Investigational Site

    Greater Sudbury, Ontario, P3E 1X3

  • Pfizer Investigational Site

    Halifax, Nova Scotia, B3H 2E2

  • Pfizer Investigational Site

    Kingston, Ontario, K7L 4X3

  • Pfizer Investigational Site

    London, Ontario, N6A 4G5

  • Pfizer Investigational Site

    Markham, Ontario, L6B 1A1

  • Pfizer Investigational Site

    Medicine Hat, Alberta, T1A 4C2

  • Pfizer Investigational Site

    Medicine Hat, Alberta, T1B 4E7

  • Pfizer Investigational Site

    Mississauga, Ontario, L5M 4N4

  • Pfizer Investigational Site

    Montreal, Quebec, H1N 3M5

  • Pfizer Investigational Site

    Montreal, Quebec, H1N 3V2

  • Pfizer Investigational Site

    Montreal, Quebec, H3A 1A1

  • Pfizer Investigational Site

    Ottawa, Ontario, K1H 8K7

  • Pfizer Investigational Site

    Penticton, British Columbia, V2A 4M4

  • Pfizer Investigational Site

    Red Deer, Alberta, T4N 1T6

  • Pfizer Investigational Site

    Saskatoon, Saskatchewan, S7K 3H3

  • Pfizer Investigational Site

    St. John's, Newfoundland and Labrador, A1E 4J8

  • Pfizer Investigational Site

    Sydney, Nova Scotia, B1P 1C6

  • Pfizer Investigational Site

    Sydney, Nova Scotia, B1P 1E1

  • Pfizer Investigational Site

    Toronto, Ontario, M5T 1R8

  • Pfizer Investigational Site

    Toronto, Ontario, M6J 1H4

  • Pfizer Investigational Site

    Verdun, Quebec, H4H 1R3

  • Pfizer Investigational Site

    Victoria, British Columbia, V8R 4Z3

  • Pfizer Investigational Site

    Windsor, Ontario, N9C 3Z4

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3A 1R9

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3E 3N4

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3K 2E2

  • Pfizer Investigational Site

    Winnipeg, Manitoba, R3P 0N5

Other trials in Canada

About this study

Official title: A One-Year, Phase IV, Open-Label, Non-Comparative Trial Of The Effect Of Ziprasidone HCL On Metabolic Syndrome Risk Factors In Patients With Psychotic Disorders

The purpose of this study is to explore the impact of ziprasidone on the distribution of metabolic syndrome risk factors in a population of patients presenting with glucose intolerance, dyslipidemia and/or elevated waist circumference associated with their current antipsychotic medication.

Read the detailed description

The trial was terminated prematurely on May 24, 2012, due to changes in organizational strategy and resources. The decision to terminate the trial was not based on any safety or efficacy concerns.

Being tested
Ziprasidone HCL (oral)
Keywords
Ziprasidone, metabolic syndrome, risk factors, schizophrenia, psychotic disorders.
Medical subject headings
Schizophrenia Spectrum and Other Psychotic Disorders, Metabolic Syndrome, Schizophrenia, Psychotic Disorders

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Ziprasidone HCL (oral)Drug

    Also called Zeldox, Geodon

    Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.

Study groups in NCT00748566
Study groupRoleWhat they receive
Active treatment (switch to oral Ziprasidone)ExperimentalNot described
Receives: Drug: Ziprasidone HCL (oral)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Percentage of Participants Achieving at Least 1 Risk Factor Reduction From Baseline for Metabolic Syndrome (MS)

    MS risks factors: elevated (el) waist, men:>=102 centimeters(cm), women:>=88 cm (Asian origin:>=90 cm in men, >=80 cm in women); el triglycerides: >=1.7 millimoles per liter (mmol/L) (>=150 milligram per deciliter [mg/dL]); reduced high-density lipoprotein cholesterol (HDL-C), men:<1.03 mmol/L (<40 mg/dL), women:<1.3 mmol/L (<50 mg/dL); el fasting glucose: >=5.6 mmol/L (>=100 mg/dL); el systolic/diastolic blood pressure (SBP/DBP): SBP>=130 millimeters of mercury (mmHg) and/or DBP>=85 mmHg. Responder=at least 1 less risk factor at endpoint (premature discontinuation or Week 52) than baseline.

    Measured: Endpoint (premature discontinuation or Week 52)

Secondary outcomes (24)
  1. Mean Change From Baseline in the Number of Risk Factors of Metabolic Syndrome (MS) at Week 4, 12, 28 and 52

    MS risks factors: elevated waist circumference: greater than or equal to (>=)102 cm in men, >=88 cm in women (Asian origin: >=90 cm [men], >=80 cm [women]); elevated triglycerides: >=1.7 mmol/L (>=150 mg/dL); reduced high-density lipoprotein cholesterol (HDL-C): less than (<)1.03 mmol/L (<40 mg/dL) in men, <1.3 mmol/L (<50 mg/dL) in women; elevated fasting glucose: >=5.6 mmol/L (>=100 mg/dL); elevated SBP/DBP: SBP >=130 mmHg and/or DBP >=85 mmHg.

    Measured: Baseline, Week 4, 12, 28, 52

  2. Percentage of Participants With Metabolic Syndrome (MS)

    According to the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII), metabolic syndrome is defined as a condition that includes 3 or more of 5 characteristics: abdominal obesity, hypertriglyceridemia, low high-density lipoprotein (HDL) cholesterol, high blood pressure, and high fasting glucose.

    Measured: Baseline, Week 4, 12, 28, 52

  3. Number of Participants With Change From Baseline in Metabolic Syndrome (MS) Risk Factors at Week 4, 12, 28 and 52

    MS risks factors: elevated waist circumference: >=102 cm in men, >=88 cm in women (Asian origin: >=90 cm [men], >=80 cm [women]); elevated triglycerides: >=1.7 mmol/L (>=150 mg/dL); reduced high-density lipoprotein cholesterol (HDL-C): <1.03 mmol/L (<40 mg/dL) in men, <1.3 mmol/L (<50 mg/dL) in women; elevated fasting glucose: >=5.6 mmol/L (>=100 mg/dL); elevated SBP/DBP: SBP >=130 mmHg and/or DBP >=85 mmHg.

    Measured: Week 4, 12, 28, 52

  4. Percentage of Participants With Individual Risk Factors of Metabolic Syndrome (MS)

    MS risks factors: elevated waist circumference: >=102 cm in men, >=88 cm in women (Asian origin: >=90 cm [men], >=80 cm [women]); elevated triglycerides: >=1.7 mmol/L (>=150 mg/dL); reduced high-density lipoprotein cholesterol (HDL-C): <1.03 mmol/L (<40 mg/dL) in men, <1.3 mmol/L (<50 mg/dL) in women; elevated fasting glucose: >=5.6 mmol/L (>=100 mg/dL); elevated SBP/DBP: SBP >=130 mmHg and/or DBP >=85 mmHg.

    Measured: Baseline, Week 4, 12, 28, 52

  5. Change From Baseline in Waist Circumference at Week 4, 12, 28 and 52

    Waist circumference data is reported separately for male and female participants.

    Measured: Baseline, Week 4, 12, 28, 52

  6. Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at Week 4, 12, 28 and 52

    BP measurement is recorded as systolic BP (SBP, BP when heart is contracting; it is the maximum arterial pressure during contraction of left ventricle) and diastolic BP (DBP, BP when heart is relaxing; it is the minimum arterial pressure during relaxation and dilation of ventricles).

    Measured: Baseline, Week 4, 12, 28, 52

  7. Change From Baseline in Triglyceride and High Density Lipoprotein-Cholesterol (HDL-C) Levels at Week 4, 12, 28 and 52

    Triglyceride data is reported for whole study population whereas HDL-C data is reported separately for male and female participants.

    Measured: Baseline, Week 4, 12, 28, 52

  8. Change From Baseline in Fasting Glucose Level at Week 4, 12, 28 and 52

    Measured: Baseline, Week 4, 12, 28, 52

  9. Change From Baseline in 10-year Cardiovascular Heart Disease (CHD) Risk According to Framingham Scoring System at Week 4, 12, 28 and 52

    Framingham scoring system risk factors: age (risk points range: -9 to 16), cholesterol (risk points range: 0 to 13), HDL cholesterol (risk points range: -1 to 2), smoking (risk points range: 0 to 9), and systolic blood pressure (risk points range: 0 to 6); total risk points range <0 to >=25, higher score indicates higher CHD risk. The risk points are transformed to 10-year risk percentage for CHD which ranges from <1% to >=30%, where higher percent indicates greater risk for CHD.

    Measured: Baseline, Week 4, 12, 28, 52

  10. Change From Baseline in Total Cholesterol (TC) and Low Density Lipoprotein-Cholesterol (LDL-C) Levels at Week 4, 12, 28 and 52

    Measured: Baseline, Week 4, 12, 28, 52

  11. Change From Baseline in Weight at Week 4,12, 28 and 52

    Measured: Baseline, Week 4, 12, 28, 52

  12. Change From Baseline in Body Mass Index (BMI) at Week 4, 12, 28 and 52

    Body mass index calculated as weight in kilograms (kg) divided by height in (meters) squared (m)^2 .

    Measured: Baseline, Week 4, 12, 28, 52

  13. Change From Baseline in Glycosylated Hemoglobin (HbA1c) Concentration at Week 4, 12, 28 and 52

    HbA1c is a form of hemoglobin that is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.

    Measured: Baseline, Week 4, 12, 28, 52

  14. Change From Baseline in Insulin Level at Week 4, 12, 28 and 52

    Measured: Baseline, Week 4, 12, 28, 52

  15. Change From Baseline in the Physical Activity Index Score at Week 28 and 52

    Physical activity (exercise) score derived for each participant based on the frequency and intensity of physical activities: regular walking, recreational activity, cycling, and sporting activity. Six categories of total score: inactive (range: 0-2), occasional (range: 3-5), light (range: 6-8), moderate (range: 9-12), moderately vigorous (range: 13-20), and vigorous (>=21). Higher total score = higher frequency and intensity of physical activity.

    Measured: Baseline, Week 28, 52

  16. Change From Baseline in QT Interval Corrected for Heart Rate (QTc) at Week 4, 12, 28 and 52

    QT interval is the time between the start of the Q wave and the end of the T wave in the cardiac electrical cycle. QTc is the QT interval corrected for heart rate. Corrected QT interval using Fridericia's heart rate correction formula: QTcF = QT/RR^1/3, where RR=RR interval in seconds (60 divided by heart rate).

    Measured: Baseline, Week 4, 12, 28, 52

  17. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score, Positive and Negative Subscale Scores at Week 12, 28 and 52

    Assesses positive and negative symptoms, general psychopathology specifically associated with schizophrenia. Scale consists of 30 items, each rated on scale from 1 (symptom not present) - 7 (symptoms extremely severe). Sum of 30 items is defined as PANSS total score, range:30-210. 7 items make up positive scale (delusions, conceptual disorganization, hallucinatory behavior); total range: 7-49. 7 items make up negative scale (blunted affect, emotional withdrawal, poor rapport, passive/apathetic social withdrawal); total range: 7-49. For each subscale, total score: higher score=greater severity.

    Measured: Baseline, Week 12, 28, 52

  18. Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Week 12, 28 and 52

    CGI-S is a single-item, clinician-rated scale that assesses the global severity of the participants overall illness. CGI-S ratings range from 1 (normal, not at all ill) to 7 (among the most severely ill participants).

    Measured: Baseline, Week 12, 28, 52

  19. Clinical Global Impression-Improvement (CGI-I) Scale Score

    CGI-I is a single-item, clinician-rated scale that assesses global improvement in the participants clinical state in response to study treatment, and as compared to their status at pre-treatment baseline. Possible CGI-I scores range from 1 to 7, where 1=very much improved, 4=no change and 7=very much worse.

    Measured: Endpoint (premature discontinuation or Week 52)

  20. Change From Baseline in Drug-Attitude Inventory-30-Item Scale (DAI-30) Score at Week 28 and 52

    DAI, a 30-item scale measuring subjective responses to medication (including acceptability and tolerability which aims to understand the factors influencing treatment adherence). Scale has 15 items (statements) scored as true and 15 items scored as false. An overall calculated score ranged from -15 to 15, where a positive score indicated a positive subjective response (compliant), a negative score indicated non-compliance.

    Measured: Baseline, Week 28, 52

  21. Change From Baseline in Social and Occupational Functioning Assessment Scale (SOFAS) Score at Week 28 and 52

    SOFAS: a 0-100 single score scale focusing exclusively on participant's level of social and occupational functioning; not directly influenced by overall severity of participant's psychological symptoms; higher score = higher level of functioning.

    Measured: Baseline, Week 28, 52

  22. Change From Baseline in European Quality of Life (EuroQoL) - 5 Dimensions Index (EQ-I) Score at Week 28 and 52

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Measured: Baseline, Week 28, 52

  23. Changes From Baseline in European Quality of Life (EuroQoL) - 5 Dimensions Visual Analog Scale (VAS) Score at Week 28 and 52

    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Measured: Baseline, Week 28, 52

  24. Change From Baseline in Columbia Suicide Severity Rating Scale (C-SSRS) Score at Week 1, 2, 4, 8, 12, 20, 28, 36, 44 and 52

    C-SSRS assessed whether participant experienced following: completed suicide(1), suicide attempt(2) (response of "Yes" on "actual attempt"), preparatory acts toward imminent suicidal behavior(3)("Yes" on "preparatory acts or behavior"), suicidal ideation(4) ("Yes" on "wish to be dead", "non-specific active suicidal thoughts", "active suicidal ideation with methods without intent to act/some intent to act, without specific plan or with specific plan and intent), any suicidal behavior or ideation, self-injurious behavior(7)("Yes" on "Has subject engaged in non-suicidal self-injurious behavior").

    Measured: Baseline, Week 1, 2, 4, 8, 12, 20, 28, 36, 44 and 52

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Sep 2008 (estimated)
  2. Study startDec 2008
  3. Primary completionMay 2012
  4. Study completionMay 2012

Why it stopped: See Detailed Description

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
172 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00748566
Sponsor's protocol ID
A1281173
Status last verified
Mar 2021
First submitted
5 Sep 2008
Last updated
3 Mar 2021
Data monitoring committee
No

Publications

  • Chue P, Mandel FS, Therrien F. The effect of ziprasidone on metabolic syndrome risk factors in subjects with schizophrenia: a 1 year, open-label, prospective study. Curr Med Res Opin. 2014 Jun;30(6):997-1005. doi: 10.1185/03007995.2014.898139. Epub 2014 Mar 17.

    PubMed 24568177

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing Ziprasidone HCL (oral) in people with Schizophrenia and Disorders With Psychotic Features, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 32 sites in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 3 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 32 sites in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 19 Jun 2013). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Percentage of Participants Achieving at Least 1 Risk Factor Reduction From Baseline for Metabolic Syndrome (MS) (time frame: Endpoint (premature discontinuation or Week 52)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00748566, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Mar 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in